Regulus Therapeutics Inc. [NASDAQ: RGLS] slipped around -0.08 points on Wednesday, while shares priced at $1.39 at the close of the session, down -5.44%. The company report on February 10, 2021 that Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), announced it has completed enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS4326. The Phase 1b is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD. The study is designed to evaluate the safety, pharmacokinetics, and changes in levels of polycystin 1 (PC1) and polycystin 2 (PC2) in patients with ADPKD administered RGLS4326 every other week for a total of four doses. The dose level for the first cohort is 1mg/kg of RGLS4326 and the dose level for the second cohort is 0.3mg/kg. The third and final cohort will be dosed at a level to be determined based on the results of the first two cohorts. Concurrent with completion of enrollment in the first cohort and based on the review of the available interim safety data, the first patient of the second cohort has received the first dose of RGLS4326.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
“We are pleased to have reached this important step in our ongoing RGLS4326 program for the treatment of ADPKD,” said Jay Hagan, CEO of Regulus. “To date, no serious adverse events have been reported and results from the first cohort are expected to be available early in the second quarter of this year.”.
Regulus Therapeutics Inc. stock is now 2.96% up from its year-to-date (YTD) trading value. RGLS Stock saw the intraday high of $1.5369 and lowest of $1.38 per share. The company’s 52-week high price is 1.97, which means current price is +25.23% above from all time high which was touched on 02/17/21.
Compared to the average trading volume of 2.53M shares, RGLS reached a trading volume of 2287598 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Regulus Therapeutics Inc. [RGLS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RGLS shares is $1.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RGLS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR Inc. have made an estimate for Regulus Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2018. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on January 05, 2018, representing the official price target for Regulus Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Chardan Capital Markets kept a Buy rating on RGLS stock. On March 06, 2017, analysts decreased their price target for RGLS shares from 8 to 6.
The Average True Range (ATR) for Regulus Therapeutics Inc. is set at 0.20, with the Price to Sales ratio for RGLS stock in the period of the last 12 months amounting to 10.59. The Price to Book ratio for the last quarter was 6.95, with the Price to Cash per share for the same quarter was set at 0.47.
How has RGLS stock performed recently?
Regulus Therapeutics Inc. [RGLS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.20. With this latest performance, RGLS shares gained by 8.59% in over the last four-week period, additionally plugging by 146.06% over the last 6 months – not to mention a rise of 78.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RGLS stock in for the last two-week period is set at 44.24, with the RSI for the last a single of trading hit 37.69, and the three-weeks RSI is set at 48.26 for Regulus Therapeutics Inc. [RGLS]. The present Moving Average for the last 50 days of trading for this stock 1.3936, while it was recorded at 1.6420 for the last single week of trading, and 0.8452 for the last 200 days.
Regulus Therapeutics Inc. [RGLS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Regulus Therapeutics Inc. [RGLS] shares currently have an operating margin of -246.40. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13.
Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Additionally, RGLS Total Debt to Total Capital is recorded at 43.36, with Total Debt to Total Assets ending up at 36.42. Long-Term Debt to Equity for the company is recorded at 0.28, with the Long-Term Debt to Total Capital now at 0.16.
Reflecting on the efficiency of the workforce at the company, Regulus Therapeutics Inc. [RGLS] managed to generate an average of -$885,333 per employee. Receivables Turnover for the company is 11.71 with a Total Asset Turnover recorded at a value of 0.20.Regulus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
Earnings analysis for Regulus Therapeutics Inc. [RGLS]
With the latest financial reports released by the company, Regulus Therapeutics Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc. go to 39.60%.
Insider trade positions for Regulus Therapeutics Inc. [RGLS]
There are presently around $26 million, or 71.00% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 6,451,056, which is approximately 214.309% of the company’s market cap and around 7.30% of the total institutional ownership; BVF INC/IL, holding 3,376,207 shares of the stock with an approximate value of $4.69 million in RGLS stocks shares; and POINT72 ASSET MANAGEMENT, L.P., currently with $4.47 million in RGLS stock with ownership of nearly New of the company’s market capitalization.
Positions in Regulus Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 18 institutional holders increased their position in Regulus Therapeutics Inc. [NASDAQ:RGLS] by around 10,914,435 shares. Additionally, 11 investors decreased positions by around 401,532 shares, while 8 investors held positions by with 7,096,150 shares. The mentioned changes placed institutional holdings at 18,412,117 shares, according to the latest SEC report filing. RGLS stock had 10 new institutional investments in for a total of 5,936,505 shares, while 8 institutional investors sold positions of 373,758 shares during the same period.